Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_assertion type Assertion NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_head.
- NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_provenance.
- NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_assertion evidence source_evidence_literature NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_provenance.
- NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_assertion SIO_000772 22025528 NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_provenance.
- NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_assertion wasDerivedFrom befree-2016 NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_provenance.
- NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_assertion wasGeneratedBy ECO_0000203 NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_provenance.